SPG Block for Acute Pediatric Migraine

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Newark Beth Israel Medical Center
• Treatments: Lidocaine; Prochlorperazine

Criteria

Inclusion Criteria:

• Frontal migraine headache

Exclusion Criteria:

• Non-english speaking

• Known pregnancy

• Sickle cell hemaglobinopathy

• Concern for CNS infection

• Acute febrile illness

• non-frontal headaches

• Concern for increased intracranial pressure